Viyash Scientific Limited, formerly known as Sequent Scientific Limited, has announced significant leadership changes and a revision to its employee incentive structure following a Board meeting held on April 22, 2026. The company has officially appointed two senior representatives from the Carlyle Group, Mr. Amit Jain and Mr. Abhiroop Jayanthi, as Additional Non-Executive, Non-Independent Directors. Additionally, the Board approved a reduction in the proposed ESOP 2026 pool from 1,34,75,000 to 1,30,98,000 stock options.

The appointment of these seasoned private equity professionals signals a strategic deepening of the relationship between Viyash and its major backer, the Carlyle Group. Mr. Amit Jain serves as a Partner and Head of Carlyle India Advisors, bringing extensive experience from Blackstone and McKinsey, while Mr. Abhiroop Jayanthi is a Managing Director at Carlyle with a strong focus on healthcare and life sciences investments. Their induction follows the recent resignation of previous directors and is intended to guide the company’s growth in the global pharmaceutical landscape. The meeting, which commenced at 11:30 a.m. and concluded at 12:39 p.m., also finalized the technical adjustments to the company’s 2026 employee stock option scheme.

Viyash Scientific is a leading integrated pharmaceutical company with a specialized focus on Animal Health APIs and formulations, maintaining a global footprint across over 100 countries. In 2025, the company reached a major milestone with the successful merger of Viyash Lifesciences Private Limited and Symed Labs into the entity formerly known as Sequent Scientific. This consolidation has created a diversified business profile with nine manufacturing facilities in India and an international presence in markets like Spain, Turkey, Brazil, and the US. Recent updates from late 2025 include the National Company Law Tribunal (NCLT) sanctioning the composite scheme of amalgamation, effectively integrating these diverse operations under the unified “Viyash” brand to drive operational efficiency in the human and animal health segments.

The company’s financial performance in 2025 showed robust growth, with consolidated revenue for the quarter ended December 31, 2025, reaching ₹858.4 Crore, a 10.9% increase year-on-year. For the nine-month period ending December 2025, revenue climbed to ₹2,500.4 Crore, while Profit After Tax (PAT) surged by 230% to ₹158.3 Crore compared to the previous year. The Carlyle Group remains the company’s most prominent investor, holding a 30.2% stake as of December 31, 2025, alongside CA Harbor Investments which holds 31.2%. Other notable institutional investors include quant Money Managers Ltd. and various global asset management firms, reflecting strong confidence in the company’s post-merger trajectory.